A 70-year-old man with urothelial cancer of the bladder (UBC) metastatic to the pelvic and retroperitoneal lymph nodes was treated with gemcitabine plus cisplatin, but after two cycles neutropenic sepsis developed, which required a prolonged intensive care unit admission. Upon recovery, repeat imaging studies revealed progressive pelvic and retroperitoneal lymphadenopathy, and the patient enrolled in a clinical trial that evaluated treatment with an anti-PD-L1 antibody. The patient achieved a complete radiographic response to immune checkpoint blockade, which continued for 18 months after initiating therapy (Fig 1). However, at that time, a cystoscopy of his primary tumor and a transurethral resection revealed residual muscle-invasive UBC. The patient asked whether there is any role for definitive local therapy of his primary bladder tumor with radical cystectomy or radiation.

Original languageEnglish
Pages (from-to)3495-3498
Number of pages4
JournalJournal of Clinical Oncology
Issue number29
StatePublished - 10 Oct 2016


Dive into the research topics of 'Definitive management of primary bladder tumors in the context of metastatic disease: Who, how, when, and why?'. Together they form a unique fingerprint.

Cite this